The forest plot about the pooled sensitivity and specificity for the diagnostic value of SCCa on the lymph node metastasis was drawn.

<p>And the heterogeneity could be determined on the figure. The Irawn. And the heterogeneity could be determined on the figure. SCindicating there were heterogeneity between studies.(I²>50 suggested heterogeneity existed). The pooled sensitivity was 0.7 and specificity was 0.63, indicating a medium diagnostic power.</p

SROC curve was drawn in this meta-analysis.

<p>The random effect model was used via bivariate model (Fig 4A) and HSROC model (Fig 4B). The pooled sensitivity and specificity were 0.70 and 0.63 respectively. AUC was 0.73 indicating a medium diagnostic value.</p

The bivariate boxplot about the heterogeneity was drawn.

<p>It demonstrated that 3 sets of data were out of the circles, which indicated there was heterogeneity between articles we included.</p

The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review

<div><p>Background</p><p>The diagnostic power of CT or MRI on the lymph node status was limited. Supplement measurements were needed to assist the diagnosis of lymph node metastasis. The SCCa was reported to be close related to lymph node status. But currently the clinical value of serum SCCa measurement in lymph node status has not been clearly defined. This meta-analysis was to investigate this topic on a large scale.</p><p>Method</p><p>Searching the Pubmed, Embase, Cochrane library, CNKI and Wanfang database for SCC-Ag/SCCA/SCC-antigen and cervical cancer/tumor/carcinoma/neoplasm published in any language from Jan 1 1990 to Aug 1 2017. QUADAS (quality assessment of diagnostic accuracy studies) was used to evaluate the quality of the articles. An eligible set of data should include true positive, true negative, false positive and false negative number. Every set of data was extracted and analyzed by STATA 14.0. The forest plot and bivariate boxplot were utilized to evaluate the heterogeneity. The funnel graph was used to test the publication bias. The SROC curve was draw via random effect model and HSROC model.</p><p>Result</p><p>17 sets of data and 3985 patients were included for the diagnostic meta-analysis. There was heterogeneity, which was partially from SCCa cut-off value. The pooled sensitivity was 0.70 and specificity was 0.63. AUC was 0.73. Eight articles provided the relative risk value of lymphatic metastasis when SCCa increased. The relative risk of lymph node metastasis increased ranging from 2.3–40 as with different SCCa cut off value.</p><p>Conclusion</p><p>The diagnostic value of SCCa for lymph nodal metastasis was medium and it was strongly related to lymph node status. Thus SCCa could assist imaging tests to detect lymph node metastasis. Besides, it was correlated with para-aortic lymph node metastasis.</p></div

The funnel plot about the publication bias was drawn.

<p>As can be seen no asymmetry was found in the funnel plot, indicating low likelihood of publication bias.</p

The general characteristics of the including studies.

<p>The general characteristics of the including studies.</p

The PRISMA flow diagram of literature screening.

<p>13 articles meet the inclusion and exclusion requirement eventually and were eligible for the meta-analysis.</p

The articles which provided the information about the relationship between the elevated SCCa and the risk of pelvic nodal metastasis.

<p>The articles which provided the information about the relationship between the elevated SCCa and the risk of pelvic nodal metastasis.</p

The results of quality evaluation of QUADAS.

<p>The results of quality evaluation of QUADAS.</p

Forest plot of prevalence of sarcopenia in COPD.

Sarcopenia prevalence and its risk factors in chronic obstructive pulmonary disease (COPD) vary partly due to definition criteria. This systematic review aimed to identify the prevalence and risk factors of sarcopenia in COPD patients. This review was registered in PROSPERO (CRD42022310750). Nine electronic databases were searched from inception to September 1st, 2022, and studies related to sarcopenia and COPD were identified. Study quality was assessed using a validated scale matched to study designs, and a meta-analysis was performed to evaluate sarcopenia prevalence. COPD patients with sarcopenia were compared to those without sarcopenia for BMI, smoking, and mMRC. The current meta-analysis included 15 studies, with a total of 7,583 patients. The overall sarcopenia prevalence was 29% [95% CI: 22%–37%], and the OR of sarcopenia in COPD patients was 1.51 (95% CI: 1.19–1.92). The meta-analysis and systematic review showed that mMRC (OR = 2.02, P = 0.04) and age (OR = 1.15, P = 0.004) were significant risk factors for sarcopenia in COPD patients. In contrast, no significant relationship was observed between sarcopenia and smoking and BMI. Nursing researchers should pay more attention to the symptomatic management of COPD and encourage patients to participate in daily activities in the early stages of the disease.</div